Krystal Biotech FY2025 EPS Estimate Lowered by William Blair

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities research analysts at William Blair reduced their FY2025 earnings per share estimates for shares of Krystal Biotech in a report issued on Monday, July 14th. William Blair analyst S. Corwin now expects that the company will post earnings of $5.43 per share for the year, down from their prior estimate of $5.89. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The business had revenue of $88.18 million for the quarter, compared to analysts’ expectations of $98.66 million.

A number of other equities analysts have also recently issued reports on the company. Citigroup restated a “neutral” rating and set a $176.00 price objective (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. Chardan Capital restated a “buy” rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Guggenheim dropped their price objective on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Finally, HC Wainwright restated a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, June 24th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $213.75.

Krystal Biotech Stock Down 1.8%

KRYS opened at $147.73 on Tuesday. The business has a fifty day moving average of $135.75 and a 200 day moving average of $156.11. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $219.34. The stock has a market cap of $4.27 billion, a P/E ratio of 35.51 and a beta of 0.67.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 6,927 shares of the company’s stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $150.27, for a total value of $1,040,920.29. Following the completion of the sale, the insider directly owned 1,525,929 shares in the company, valued at approximately $229,301,350.83. This represents a 0.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 13,927 shares of company stock valued at $2,092,852. 13.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds have recently made changes to their positions in the company. Teacher Retirement System of Texas lifted its holdings in shares of Krystal Biotech by 27.3% in the 4th quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company’s stock worth $1,000,000 after buying an additional 1,369 shares during the period. Fifth Third Bancorp raised its position in shares of Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after acquiring an additional 105 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Krystal Biotech in the 4th quarter worth $15,989,000. JPMorgan Chase & Co. raised its position in shares of Krystal Biotech by 18.7% in the 4th quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company’s stock worth $23,786,000 after acquiring an additional 23,934 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in shares of Krystal Biotech by 1.8% in the 4th quarter. Federated Hermes Inc. now owns 13,048 shares of the company’s stock worth $2,044,000 after acquiring an additional 229 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).